Inertia – a possible reason for not reaching LDL-cholesterol targets: results of a multicenter observational study
Authors:
Michal Vrablík 1; Ivana Šarkanová 2; Katarína Breciková 2; Petra Šedová 3,4,5; Martin Šatný 1; Aleš Tichopád 6
Authors‘ workplace:
Centrum preventivní kardiologie, III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze
1; CEEOR, spol. s r. o., Praha
2; I. interní kardiologická klinika LF MU a FN U Sv. Anny v Brně
3; I. neurologická klinika a International Clinical Research Center (ICRC) LF MU a FN U Sv. Anny v Brně
4; Neurology Department, Mayo Clinic, Rochester, USA
5; Oddělení biomedicínských technologií, České vysoké učení technické v Praze
6
Published in:
AtheroRev 2024; 9(2): 73-79
Category:
Overview
Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of morbidity and mortality not only in the Czech Republic but also globally. Cholesterol carried by apolipoprotein B (apoB)-containing particles, i.e. predominantly LDL particles, is considered to be their major, i.e. causal, risk factor (RF). Although increasing attention is being paid to innovative therapies, it appears that nonadherence to treatment or (unfortunately) medical inertia is often behind the lack of control of dyslipidemia (DLP). The aim of this multicenter retrospective cross-sectional study was to map DLP control and treatment strategies in a group of patients at high or very high cardiovascular (CV) risk, in outpatient cardiologists/internists’ offices. A total of 450 patients were enrolled in the study-80% at very high CV risk and 12.7% at high CV risk; the remaining percentages were misclassified probands. Only 19.4% and 28.1% of the very high CV-risk and high-risk patients, respectively, achieved target LDL-cholesterol (LDL-C) levels. More than 60% of the treating cardiologists (despite recommended practices) preferred slow (cautious) dose titration of hypolipidemic agents; only 17% of clinicians indicated prompt modification of established therapy (dose increase, change of preparation, or addition of another drug) to achieve LDL-C reduction. A surprising finding was that over 60% of clinicians were satisfied with the current treatment, despite not achieving target lipid parameters. A very slow (unfortunately unsatisfactory) penetration of the recommended procedures into clinical practice is evident. Thus, it can be assumed that with maximum use of currently available treatment options, satisfactory control of DLP will be achieved in a large proportion of patients with minimal additional costs.
Keywords:
atherosclerotic cardiovascular diseases (ASCVD) – dyslipidemia (DLP) – (non)adherence – lipid parameters
Sources
Yusuf S, Joseph P, Rangarajan S et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 2020; 395(10226): 795–808. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(19)32008–2>.
Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 2016; 27(5): 473–483. Dostupné z DOI: <http://dx.doi.org/10.1097/MOL.0000000000000330>.
Šatný M. Dyslipidemie – známá, neznámá. [Dyslipidemia – the known unknown]. Vnitr Lek 2023; 69(5): 305–310. Dostupné z DOI: <http://dx.doi.org/10.36290/vnl.2023.060>.
Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372(25): 2387–2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>.
Giugliano RP, Cannon CP, Blazing MA et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus. Circulation 2018; 137(15): 1571–1582. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.117.030950>.
Robinson JG, Farnier M, Krempf M et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med 2015; 372(16): 1489–1499. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1501031>.
Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18): 1713–1722. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>.
Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz455>.
de Backer G, Jankowski P, Kotseva K et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019; 285: 135–146. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2019.03.014>.
Ray KK, Molemans B, Schoonen WM et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DAVINCI study. Eur J Prev Cardiol 2021; 28(11): 1279–1289. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjpc/zwaa047>.
Janský P, Rosolová H, Vrablík M. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: Summary of the document prepared by the Czech Society of Cardiology. Cor Vasa 2017; 59: e389–e415. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crvasa.2017.03.007>.
Šatný M, Tůmová E, Vrablík M. LIPIcontrol: daří se zlepšovat úroveň kontroly hlavních rizikových faktorů kardiovaskulárních onemocnění v každodenní praxi? Hypertenze KV Prevence 2018; 7(1): 15–21.
Šatný M, Tůmová E, Vrablík M. Srovnání profilu a léčby pacientů s nekontrolovanou arteriální hypertenzí a/nebo dyslipidemií v péči specialistů a v primární péči v Česku: srovnání výsledků studie LipitenCliDec 1 a LipitenCliDec 2. AtheroRev 2021; 6(3): 154–162.
Nicholls SJ, Brandrup-Wognsen G, Palmer M et al. Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER). American J Cardiol 2010; 105(1): 69–76. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2009.08.651>.
Ceska R, Latkovskis G, Ezhov M et al. The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. Current Atherosclerosis Reports. Curr Atheroscler Rep 2019; 21(9): 36. Dostupné z DOI: <http://dx.doi.org/10.1007/s11883–019–0797–3>.
Morieri ML, Perrone V, Veronesi C et al. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes. Cardiovasc Diabetol 2021; 20(1): 144. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–021–01338-y>.
Morieri ML, Lamacchia O, Manzato E et al. Physicians’ misperceived cardiovascular risk and therapeutic inertia as determinants of low LDL-cholesterol targets achievement in diabetes. Cardiovasc Diabetol 2022; 21(1): 57. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–022–01495–8>.
Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380(9841): 581–590. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(12)60367–5>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2024 Issue 2
Most read in this issue
- Diagnosis and treatment of hyperuricemia in cardiovascular prevention based on the pathophysiological mechanism of its occurrence: expert consensus of Czech and Slovak experts 2024
- The current role of lipoprotein apheresis in the context of new recommendations for hypolipidemic pharmacotherapy
- Bempedoic acid – a new player in the field of hypolipidemic therapy
- 27th Congress of Atherosclerosis